UniQure Needs Longer-Term Data For Hemophilia B Gene Therapy EtranaDez
Company Presents HOPE-B Data At R&D Day
The FDA may want longer follow-up data for companies developing treatments for hemophilia A as well as hemophilia B.
You may also be interested in...
Novartis aims to double the addressable market for its spinal muscular atrophy gene therapy – and catch up to competitors – with the intrathecal version known as OAV-101.
A patient developed Factor VIII inhibitors, but he had also recently received a COVID-19 vaccine and was genetically predisposed.
BioMarin is planning to resubmit its EU marketing application for Roctavian soon and, as with the previously pulled application, it wants the regulators to fast-track the new filing.